The deal provides PerkinElmer access to Applied BioCode's Barcoded Magnetic Bead technology, including the BioCode MDx 3000 instrument.
The firm also said it had a net loss of $7.9 million, or $3.50 per share, in 2014, compared to a net loss of $2.4 million, or $12.23 per share, in 2013.
The method detected differences in the vaginal microbiome that matched up with patients' clinical diagnoses of vaginosis, and also their response to antibiotic treatment.
The company is using a $3 million, three-year grant to clinically validate the test, which it hopes will be the first of its kind approved by the FDA.
In a letter to a New York court, the investor alleged that Arrayit has failed to meet the terms of a settlement that was supposed to end litigation filed last year.
In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.
George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.
A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.
The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.